Becton Dickinson & Co Stock Price, News & Analysis

On April 1, 2021, BD (Becton, Dickinson and Company) announced that the FDA granted Emergency Use Authorization (EUA) for its rapid antigen test, the BD Veritor™ Plus System, to screen asymptomatic individuals for SARS-CoV-2 through serial testing. This authorization allows testing twice over two to three days, enhancing the detection of COVID-19 and supporting efforts to return to normalcy. The system facilitates testing in various settings like schools and workplaces, addressing public health reporting challenges through a collaboration with ImageMover for efficient data management.

BD (Becton, Dickinson and Company) announces that the FDA has granted emergency use authorization (EUA) for a rapid antigen test capable of detecting SARS-CoV-2, influenza A, and influenza B in a single test. The BD Veritor™ Plus System test will be available this summer, enabling healthcare providers to distinguish between these viral infections quickly. The test delivers results in about 15 minutes, streamlining the diagnostic process during the flu season. BD currently has over 70,000 active testing systems across multiple healthcare settings.

BD (Becton, Dickinson and Company) has partnered with ImageMover to launch a mobile app that enhances the reporting of SARS-CoV-2 antigen testing results from the BD Veritor™ Plus System. This app aims to simplify data collection at everyday settings like schools and businesses, addressing the challenges of managing test subject demographics and reporting. Available immediately, the ImageMover app provides secure, automated reporting to health authorities, streamlining the process for organizations lacking sophisticated IT infrastructure. The partnership supports BD's innovation in COVID-19 testing solutions.

BD (Becton, Dickinson and Company) has acquired GSL Solutions, Inc., a company specializing in smart medication devices that enhance the security and efficiency of medication storage and compliance. This acquisition aims to bolster BD's medication management capabilities in retail pharmacies and outpatient settings. BD sees this as a strategic move to address growing market demands for automated tracking of medications. GSL's technology includes RFID-based systems that improve operational efficiency and reduce patient wait times. The transaction is expected to be immaterial financially.

BD (Becton, Dickinson and Company) (NYSE: BDX) announced a collaboration with Scanwell Health to develop an at-home rapid test for SARS-CoV-2. This new test will utilize a BD antigen test paired with Scanwell's mobile app, offering step-by-step instructions for sample collection. Users can analyze results using their device's camera, with plans for automated reporting to health agencies. The initiative aims to enhance COVID-19 testing accessibility. BD has played a significant role in the COVID-19 response, providing a range of diagnostic solutions.

BD (Becton, Dickinson and Company) announced its participation in two upcoming virtual investor conferences. The company will present at the Leerink Virtual 10th Annual Global Healthcare Conference on February 24, 2021, at 1:00 p.m. ET, and the Raymond James Virtual 42nd Annual Institutional Investors Conference on March 2, 2021, at 8:20 a.m. ET. Interested investors can access live webcasts and replays on the BD corporate website.

BD (Becton, Dickinson and Company) has received Emergency Use Authorization (EUA) from the FDA for a new molecular diagnostic test that detects both SARS-CoV-2 and Influenza A+B within 2-3 hours. This test is designed to identify variants from the U.K. and South Africa, with 99.9% match to genetic sequences of these variants. The BD SARS-CoV-2/Flu assay operates on the BD MAX™ System, a platform that can analyze hundreds of samples daily. The product is now available in the U.S. and Europe as part of BD's ongoing response to COVID-19.

BD (Becton, Dickinson and Company) reported first fiscal quarter revenues of $5.315 billion, a 25.8% increase year-over-year, driven by $867 million from COVID-19 diagnostics. Diluted EPS rose to $3.35, up 285.1% from the previous year. The BD Medical segment saw revenues of $2.261 billion, while BD Life Sciences grew to $1.979 billion, reflecting significant COVID-19 contributions. BD expects fiscal 2021 revenue growth of 12% to 14% and adjusted EPS of $12.75 to $12.85, indicating robust financial momentum.

BD (Becton, Dickinson and Company) announced positive outcomes from the CLEAN3 trial, demonstrating that its vascular care solution significantly reduces peripheral intravenous catheter (PIVC) failures, showing rates of 34.8% versus 47.5% in the control group. The trial observed enhanced performance regarding antiseptics, with catheter colonization at 0.9% compared to 16.9%. Conducted at Poitiers University Hospital, France, the study involved around 1,000 patients, highlighting the benefits of BD’s integrated solution for improving patient safety and reducing hospital costs.